title: Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
abstract: Multidrug resistance-associated protein (MRP) is the major candidate molecule responsible for non-P-glycoprotein (PGp)-mediated multidrug resistance. We used a hammerhead anti-MRP ribozyme (alpha MRP-Rz) to inactivate MRP function in a multidrug resistant cancer cell line, KB8-5. The beta-actin promoter-driven alpha MRP-Rz sequence (pH beta/alpha MRP-Rz) was introduced into KB8-5 cells (KB8-5/alpha MRP-Rz) and we evaluated growth of the cell line. The gene expression of multidrug resistance-related molecules was estimated. Drug sensitivity was estimated by MTT assay in vitro. MRP mRNA expression was decreased in KB8-5/alpha MRP-Rz cells. The MTT assay showed increased IC50 values or resistance to doxorubicin (DOX), etoposide (VP-16) and cisplatin (CDDP) in KB8-5/alpha MRP-Rz cells. No significant differences were observed in expression of multidrug resistance gene (MDR1), thymidylate synthase, glutathione S-transferase pi or topoisomerase II alpha. The hammerhead ribozyme-mediated simple suppression of MRP mRNA expression was not sufficient to reverse multidrug resistance in the cancer cell line KB8-5.
authors.affiliation: Department of Pathology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hatanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Abe
authors.forename: M
authors.initials: M
authors.lastname: Naruke
authors.forename: S
authors.initials: S
authors.lastname: Asai
authors.forename: H
authors.initials: H
authors.lastname: Miyachi
authors.forename: T
authors.initials: T
authors.lastname: Kawakami
authors.forename: J
authors.initials: J
authors.lastname: Nagata
authors.forename: J
authors.initials: J
authors.lastname: Kamochi
authors.forename: H
authors.initials: H
authors.lastname: Kijima
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: K J
authors.initials: KJ
authors.lastname: Scanlon
authors.forename: Y
authors.initials: Y
authors.lastname: Ueyama
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D018528:ATP-Binding Cassette Transporters / Q000235:genetics*; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology; D002455:Cell Division; D002474:Cell-Free System; D002945:Cisplatin / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000494:pharmacology; D015870:Gene Expression; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D016337:RNA, Catalytic / Q000235:genetics / Q000378:metabolism*; D013940:Thymidylate Synthase / Q000235:genetics; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D002945:Cisplatin; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D004317:Doxorubicin; D005047:Etoposide; D051549:Glutathione S-Transferase pi; D005982:Glutathione Transferase; D007527:Isoenzymes; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D016337:RNA, Catalytic; D013940:Thymidylate Synthase; C427204:hammerhead ribozyme; C095122:multidrug resistance protein 3; C496556:GSTP1 protein, human